Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown. Patients and Methods ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

The exercise prescriptions also prevented other new cancers, like breast and prostate cancer. Many included just three to ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Both hand cooling and hand compression reduced the incidence of grade 2 or higher chemotherapy-induced peripheral neuropathy ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

A large prospective study suggests pro-inflammatory diets may increase risk of death in patients with stage III colon cancer, ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...